ATE265222T1 - Chemokin mutanten zur behandlung multipler sklerose - Google Patents

Chemokin mutanten zur behandlung multipler sklerose

Info

Publication number: ATE265222T1
Authority: AT; Austria
Prior art keywords: treatment; multiple sclerosis; chemokine mutants; chemokine; mutants
Prior art date: 2000-10-04

Application number

AT01986265T

Other languages

English (en)

Inventor

Amanda Proudfoot

Timothy N C Wells

Marie Kosco-Vilbois

Original Assignee

Applied Research Systems

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-04

Filing date

2001-10-03

Publication date

2004-05-15

2001-10-03 Application filed by Applied Research Systems filed Critical Applied Research Systems

2004-05-15 Application granted granted Critical

2004-05-15 Publication of ATE265222T1 publication Critical patent/ATE265222T1/de

Links

102000019034 Chemokines Human genes 0.000 title 1
108010012236 Chemokines Proteins 0.000 title 1
201000006417 multiple sclerosis Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Animal Behavior & Ethology (AREA)
Neurology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Toxicology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Enzymes And Modification Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT01986265T 2000-10-04 2001-10-03 Chemokin mutanten zur behandlung multipler sklerose ATE265222T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00121665		2000-10-04
PCT/EP2001/011428 WO2002028419A2 (en)	2000-10-04	2001-10-03	Chemokine mutants in the treatment of multiple sclerosis

Publications (1)

Publication Number	Publication Date
ATE265222T1 true ATE265222T1 (de)	2004-05-15

Family

ID=8170011

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01986265T ATE265222T1 (de)	2000-10-04	2001-10-03	Chemokin mutanten zur behandlung multipler sklerose

Country Status (30)

Country	Link
US (1)	US7402303B2 (de)
EP (1)	EP1326628B1 (de)
JP (1)	JP3908165B2 (de)
KR (1)	KR100837898B1 (de)
CN (1)	CN1285381C (de)
AR (1)	AR030854A1 (de)
AT (1)	ATE265222T1 (de)
AU (2)	AU2002215919B2 (de)
BG (1)	BG66137B1 (de)
BR (1)	BR0114407A (de)
CA (1)	CA2423616C (de)
CZ (1)	CZ303409B6 (de)
DE (1)	DE60103078T2 (de)
DK (1)	DK1326628T3 (de)
EA (1)	EA006137B1 (de)
EE (1)	EE05174B1 (de)
ES (1)	ES2217199T3 (de)
HR (1)	HRP20030215B1 (de)
HU (1)	HUP0302194A3 (de)
IL (2)	IL155178A0 (de)
MX (1)	MXPA03003008A (de)
NO (1)	NO330278B1 (de)
PL (1)	PL204231B1 (de)
PT (1)	PT1326628E (de)
RS (1)	RS50738B (de)
SI (1)	SI1326628T1 (de)
SK (1)	SK287523B6 (de)
UA (1)	UA77950C2 (de)
WO (1)	WO2002028419A2 (de)
ZA (1)	ZA200302315B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1458756B1 (de)	2001-12-17	2009-01-28	Laboratoires Serono SA	Chemokine mutanten, die als chemokine antagonisten wirken
US7335350B2 (en)	2002-04-04	2008-02-26	Laboratoires Serono Sa	Chemokines mutants having improved oral bioavailability
ATE394117T1 (de)	2002-12-23	2008-05-15	Serono Lab	Verwendung von cc-chemokine ccl5/rantes mutanten zur behandlung von lebererkrankungen
JP2007533300A (ja) *	2003-10-22	2007-11-22	アプライドリサーチシステムズエーアールエスホールディングナームロゼフェンノートシャップ	新規のｃｘｃｌ８アンタゴニスト
AT412785B (de) *	2003-12-04	2005-07-25	Kungl Andreas J Dr	Gag-bindungsproteine
DK1439191T3 (da) *	2004-01-19	2006-08-14	Ares Trading Sa	Proces til oprensning af bakterielt udtrykte proteiner
GB0412400D0 (en) *	2004-06-03	2004-07-07	Univ Newcastle	Treatment of inflammatory conditions
EP2218748B1 (de) *	2005-09-03	2012-10-10	Samsung SDI Co., Ltd.	Polybenzoxazin Verbindung, Elektrolyt-Membran enthaltend dieser Verbindung und Elektrolyt-Membran benutzende Brenndstofzell
GB0614755D0 (en)	2006-07-25	2006-09-06	Univ Geneve	Cytokine derivatives
ES2453592T3 (es)	2007-08-02	2014-04-08	Novimmune Sa	Anticuerpos anti-RANTES y métodos de uso de los mismos
EP2539354B1 (de) *	2010-02-08	2017-04-05	The Trustees Of The University Of Pennsylvania	Für rantes kodierende nukleinsäuremoleküle sowie zusammensetzungen und verfahren damit
WO2019229615A1 (en)	2018-05-28	2019-12-05	Université De Genève	Methods of inhibiting cerebral inflammation
US20250186520A1 (en) *	2020-10-26	2025-06-12	City Of Hope	Oncolytic virus compositions and methods for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5739103A (en) *	1993-11-12	1998-04-14	Dana-Farber Cancer Institute	Chemokine N-terminal deletion mutations
WO1998006751A1 (en) *	1996-08-16	1998-02-19	Research Corporation Technologies, Inc.	Mcp-3, rantes and mip-1alpha receptor antagonists
EP0906954A1 (de) *	1997-09-29	1999-04-07	Applied Research Systems ARS Holding N.V.	Aminoterminalen verkürzten C-C Chemokine als Chemokine Antagonist
ATE308617T1 (de)	1997-12-23	2005-11-15	San Raffaele Centro Fond	Rantes mutanten und deren therapeutischen anwendungen
AU2740900A (en) *	1999-01-29	2000-08-18	Millennium Pharmaceuticals, Inc.	Method of treating demyelinating inflammatory disease using ccr1 antagonists

2001
- 2001-03-10 UA UA2003044038A patent/UA77950C2/uk unknown
- 2001-10-03 US US10/398,457 patent/US7402303B2/en not_active Expired - Fee Related
- 2001-10-03 AU AU2002215919A patent/AU2002215919B2/en not_active Ceased
- 2001-10-03 EP EP01986265A patent/EP1326628B1/de not_active Expired - Lifetime
- 2001-10-03 HR HR20030215A patent/HRP20030215B1/xx not_active IP Right Cessation
- 2001-10-03 PL PL362350A patent/PL204231B1/pl not_active IP Right Cessation
- 2001-10-03 WO PCT/EP2001/011428 patent/WO2002028419A2/en not_active Ceased
- 2001-10-03 SI SI200130130T patent/SI1326628T1/xx unknown
- 2001-10-03 EE EEP200300139A patent/EE05174B1/xx not_active IP Right Cessation
- 2001-10-03 IL IL15517801A patent/IL155178A0/xx unknown
- 2001-10-03 HU HU0302194A patent/HUP0302194A3/hu unknown
- 2001-10-03 BR BR0114407-3A patent/BR0114407A/pt not_active IP Right Cessation
- 2001-10-03 CN CNB018199178A patent/CN1285381C/zh not_active Expired - Fee Related
- 2001-10-03 ES ES01986265T patent/ES2217199T3/es not_active Expired - Lifetime
- 2001-10-03 RS YUP-257/03A patent/RS50738B/sr unknown
- 2001-10-03 CA CA2423616A patent/CA2423616C/en not_active Expired - Fee Related
- 2001-10-03 PT PT01986265T patent/PT1326628E/pt unknown
- 2001-10-03 AU AU1591902A patent/AU1591902A/xx active Pending
- 2001-10-03 DK DK01986265T patent/DK1326628T3/da active
- 2001-10-03 DE DE60103078T patent/DE60103078T2/de not_active Expired - Lifetime
- 2001-10-03 JP JP2002532243A patent/JP3908165B2/ja not_active Expired - Fee Related
- 2001-10-03 MX MXPA03003008A patent/MXPA03003008A/es active IP Right Grant
- 2001-10-03 ZA ZA200302315A patent/ZA200302315B/en unknown
- 2001-10-03 SK SK406-2003A patent/SK287523B6/sk not_active IP Right Cessation
- 2001-10-03 CZ CZ20030947A patent/CZ303409B6/cs not_active IP Right Cessation
- 2001-10-03 AT AT01986265T patent/ATE265222T1/de active
- 2001-10-03 EA EA200300439A patent/EA006137B1/ru not_active IP Right Cessation
- 2001-10-03 KR KR1020037004599A patent/KR100837898B1/ko not_active Expired - Fee Related
- 2001-10-04 AR ARP010104684A patent/AR030854A1/es unknown
2003
- 2003-03-28 BG BG107685A patent/BG66137B1/bg unknown
- 2003-04-01 IL IL155178A patent/IL155178A/en not_active IP Right Cessation
- 2003-04-03 NO NO20031525A patent/NO330278B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA2423616C (en)	2010-03-16
BR0114407A (pt)	2003-07-29
SI1326628T1 (en)	2004-10-31
KR100837898B1 (ko)	2008-06-13
KR20030034238A (ko)	2003-05-01
DE60103078D1 (de)	2004-06-03
IL155178A (en)	2009-07-20
DK1326628T3 (da)	2004-08-09
AU2002215919B2 (en)	2005-11-24
SK4062003A3 (en)	2003-08-05
US7402303B2 (en)	2008-07-22
HUP0302194A3 (en)	2005-12-28
HK1062811A1 (en)	2004-11-26
MXPA03003008A (es)	2003-07-14
EA200300439A1 (ru)	2003-08-28
AU1591902A (en)	2002-04-15
CZ2003947A3 (cs)	2003-11-12
DE60103078T2 (de)	2005-04-07
YU25703A (sh)	2006-05-25
HRP20030215A2 (en)	2005-02-28
ES2217199T3 (es)	2004-11-01
HRP20030215B1 (en)	2011-09-30
AR030854A1 (es)	2003-09-03
US20040101509A1 (en)	2004-05-27
HUP0302194A2 (hu)	2003-10-28
PL204231B1 (pl)	2009-12-31
NO20031525D0 (no)	2003-04-03
WO2002028419A2 (en)	2002-04-11
ZA200302315B (en)	2004-03-25
NO20031525L (no)	2003-04-03
JP3908165B2 (ja)	2007-04-25
WO2002028419A3 (en)	2002-06-13
IL155178A0 (en)	2003-11-23
SK287523B6 (sk)	2011-01-04
PT1326628E (pt)	2004-09-30
CN1285381C (zh)	2006-11-22
UA77950C2 (en)	2007-02-15
EP1326628B1 (de)	2004-04-28
NO330278B1 (no)	2011-03-21
EE05174B1 (et)	2009-06-15
CA2423616A1 (en)	2002-04-11
CN1477969A (zh)	2004-02-25
BG66137B1 (bg)	2011-07-29
EE200300139A (et)	2003-06-16
PL362350A1 (en)	2004-10-18
JP2004510426A (ja)	2004-04-08
EA006137B1 (ru)	2005-10-27
EP1326628A2 (de)	2003-07-16
RS50738B (sr)	2010-08-31
CZ303409B6 (cs)	2012-09-05
BG107685A (bg)	2003-11-28

Legal Events

Date

Code

Title

Description

2005-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1326628

Country of ref document: EP

2011-04-15

EEFA

Change of the company name

Publication	Publication Date	Title
DE50206657D1 (de)	2006-06-08	Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
DE69918222D1 (de)	2004-07-29	Intranasale Zubereitungen zur Behandlung sexueller Störungen
DE69928542D1 (de)	2005-12-29	5ht2-agoniste zur behandlung des glaukoms
EP1438062A4 (de)	2005-06-01	Verfahren und zusammensetzungen zur behandlung von hautläsionen
DE60141230D1 (de)	2010-03-18	Verwendung von Botulinum Toxin zur Behandlung von neuralgischen Schmerzen
EP1274444A4 (de)	2006-06-14	Arzneistoffe zur behandlung psychiatrischer oder abusus-bedingter störungen
DE60128168D1 (de)	2007-06-14	Tablette und Verfahren zur Herstellung derselben
DE60123238D1 (de)	2006-11-02	Zusammensetzungen zur behandlung von autoimmunkrankheiten
AU3691301A (en)	2001-08-20	Treatment of fluorocarbon feedstocks
PL362984A1 (en)	2004-11-15	Compounds useful in the treatment of inflammatory diseases
DE10082139T1 (de)	2001-10-04	Zusammensetzung zur Behandlung von Reibungspaaren
EP1337255A4 (de)	2006-01-25	Verwendung von p38-inhibitoren zur behandlung von durch entzündungen verstärktem husten
ID27191A (id)	2001-03-08	Metode untuk pengobatan insomnia
ATE265222T1 (de)	2004-05-15	Chemokin mutanten zur behandlung multipler sklerose
DE60129907D1 (de)	2007-09-27	Verfahren zur Reinigung von Isophthalonitril
IL155174A0 (en)	2003-10-31	Methods and compositions for the treatment of inflammatory diseases
DE50105735D1 (de)	2005-04-28	Chlorzoxazon zur behandlung von psoriasis
NO20025964L (no)	2003-02-14	Ny interferon for behandling av multippel sklerose
DE60041365D1 (de)	2009-02-26	Verwendung von Riluzol zur Behandlung Multipler Sklerose
ATE299371T1 (de)	2005-07-15	Antikonvulsiva zur behandlung von autismus
AU2001267404A1 (en)	2001-11-12	Novel compounds for the treatment of inflammatory and cardiovascular diseases
AU3399401A (en)	2001-08-20	Treatment of fluorocarbon feedstocks
ATE430577T1 (de)	2009-05-15	Ppar delta-inhibitoren zur behandlung kardiovasculärer erkrankungen
GB0114231D0 (en)	2001-08-01	Treatment of multiple sclerosis
ATE251167T1 (de)	2003-10-15	Oxazinocarbazole zur behandlung von cns- erkrankungen